Do you want to read an article? Please log in or register.
Preventive potential of vaccination against herpes zoster on cardiovascular event risk
Cardiovascular Risk and Diseases
ESC 2025
Related content
Cardiovascular Risk and Diseases
Improved prediction and risk stratification of major adverse cardiovascular events using an explainable machine learning approach combining plasma biomarkers and traditional risk factors
Cardiovasc Diabetol
Zhang XR, Zhong WF, Liu RY, Huang JL, Fu JX, Gao J, Zhang PD, Liu D, Li ZH, He Y, Zhou H, Li Z
doi: 10.1186/s12933-025-02711-x
Cardiovascular Risk and Diseases
AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk : Insights From MESA and the UK Biobank
JAMA Cardiol
Bhatia HS, Ambrosio M, Razavi AC, Alebna PL, Yeang C, Spitz JA, Patel J, Tsai MY, Sperling L, Shapiro MD, Tsimikas S, Mehta A
doi: 10.1001/jamacardio.2025.1603
RECOMMENDED
Further Publications
Blood Pressure Variability and Risk of Cardiovascular Events and Mortality in Real-World Clinical Settings
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Heart Assoc
Li HL, Lin HJ, Muo CH, Lu CY, Kuo CC, Chen PC
doi: 10.1161/JAHA.124.037658
COMMENTED
Cardiovascular Risk and Diseases
Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes: a longitudinal cohort study of Swedish nationwide register data
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol
Patsoukaki V, Lind L, Lampa E, Radhi S, Eeg-Olofsson K, Eliasson B, Eriksson JW
doi: 10.1016/S2213-8587(25)00165-2
Cardiovascular Risk and Diseases
Risk acceleration by gout on major adverse cardiovascular events and all-cause death in patients with diabetes and chronic kidney disease
Diabetes Obes Metab
Lee DY, Moon JS, Jung I, Chung SM, Park SY, Yu JH, Seo JA, Han KD, Kim NH
doi: 10.1111/dom.16165
Cardiovascular Risk and DiseasesTherapy and Intervention
Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial
Lancet
Choi KH, Park YH, Lee JY, Jeong JO, Kim CJ, Yun KH, Lee HC, Chang K, Park MW, Bae JW, Doh JH, Cho BR, Kim HY, Kim W, Kim U, Rha SW, Hong YJ, Lee HJ, Ahn SG, Kim DI, Cho JH, Her SH, Jeon DS, Han SH, Lee JB, Lee CW, Kang D, Lee JM, Park TK, Yang JH, Lee SY, Choi SH, Gwon HC, Song YB, Hahn JY, SMART-CHOICE 3 investigators
doi: 10.1016/S0140-6736(25)00449-0
COMMENTED
Heart, Artery and Coronary Diseases
Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
J Am Heart Assoc
Deng Y, Polley EC, Herrin J, Swarna KS, Kent DM, Ross JS, Maron BA, Mickelson MM, McCoy RG
doi: 10.1161/JAHA.124.040217
Cardiovascular Risk and Diseases
The effectiveness of lifestyle interventions in reducing cardiovascular risk and risk factors in people with prediabetes: A systematic review and meta-analysis
Nutr Metab Cardiovasc Dis
Demissie GD, Birungi J, Shrestha A, Haregu T, Thirunavukkarasu S, Oldenburg B
doi: 10.1016/j.numecd.2025.104130
RECOMMENDED
Cardiovascular Risk and Diseases
Global Effect of Cardiovascular Risk Factors on Lifetime Estimates
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
N Engl J Med
Global Cardiovascular Risk Consortium, Magnussen C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, Aviles-Santa L, Bakker SJL, Ballantyne CM, Bernabé-Ortiz A, Bobak M, Boffetta P, Brenner H, Brunström M, Can G, Carrillo-Larco RM, Checkley W, Dallongeville J, De Bacquer D, de Gaetano G, de Lemos JA, di Carluccio E, Dobson A, Donfrancesco C, Dörr M, d'Orsi E, Drygas W, Dullaart RPF, Engström G, Ferrario MM, Ferrières J, Figtree GA, Gaye B, Ghayour-Mobarhan M, Goldbourt U, Gonzalez C, Gossling A, Grassi G, Gupta PC, He J, Hodge AM, Hozawa A, Hveem K, Iacoviello L, Ikram MK, Inoue M, Irazola V, Jobe M, Jousilahti P, Kaleebu P, Kavousi M, Kee F, Khalili D, Klotsche J, Koenig W, Kontsevaya A, Kowlessur S, Kuri-Morales P, Kuulasmaa K, Kweon SS, Lackner KJ, Landmesser U, Leistner DM, Leiva Sisnieguez CE, Leong D, Lind L, Linneberg A, Lorenz T, Lyngbakken MN, Malekzadeh R, Malyutina S, Mathiesen EB, McElduff P, Melander O, Metspalu A, Miranda JJ, Moitry M, Mugisha J, Munzinger J, Nalini M, Nambi V, Nilsson PM, Ninomiya T, Omland T, Ong SK, Oppermann K, Pajak A, Palmieri L, Panagiotakos D, Park SK, Pednekar MS, Perianayagam A, Peters A, Poustchi H, Prabhakaran D, Prentice AM, Prescott E, Quyyumi A, Risérus U, Sakata S, Salazar M, Salomaa V, Sans S, Sattler ELP, Schöttker B, Schutte AE, Sepanlou SG, Sharma SK, Shaw J, Simons LA, Söderberg S, Tamosiunas A, Tapia-Conyer R, Thorand B, Tunstall-Pedoe H, Tuomilehto J, Twerenbold R, Vanuzzo D, Veronesi G, Wannamethee SG, Watanabe M, Weimann J, Wild PS, Yao Y, Zeng Y, Ziegler A, Ojeda FM, Blankenberg S
doi: 10.1056/NEJMoa2415879